Editorially independent. Revenue never influences our rankings. · Updated weekly · Last reviewed June 9, 2026
Guide

Compounded vs Branded GLP-1

Fact-checked by Adam Kennah, M.D. on . See our fact-checking policy.

Compounded and branded GLP-1 medications contain the same active ingredient but are not the same product. This guide explains what's actually different, what isn't, and what changes with FDA shortage and enforcement status.

What's the same

  • Active ingredient. Compounded semaglutide contains semaglutide; Wegovy contains semaglutide. Same molecule.
  • Mechanism, dosing range, clinical effects. All the same at equivalent doses.
  • Side effect profile. All the same.

What's different

  • FDA approval status. Branded products are FDA-approved finished drugs. Compounded products are prepared by licensed pharmacies under federal exceptions (503A or 503B). Not FDA-approved as finished products.
  • Manufacturing standards. Branded: cGMP. 503B outsourcing facilities: also cGMP. 503A traditional compounding: USP standards but not cGMP.
  • Concentration and excipients. Branded use specific manufacturer formulations. Compounded may use different concentrations, different excipients, sometimes adjuncts (B12) not present in branded.
  • Device. Branded: calibrated pen injectors with dose dialing. Compounded: typically vials + insulin syringes.
  • Pricing. Branded $1,000+/mo list; insurance changes the math. Compounded typically cash-pay at $145–$269/month.
  • Regulatory stability of supply. Branded supply is manufacturer-controlled and stable. Compounded supply is subject to FDA shortage rules and state pharmacy oversight.

When to prefer branded

  • Insurance coverage makes branded affordable.
  • Your indication is a specific FDA-approved label (Wegovy CV, Zepbound OSA) and you want the regulator-blessed label.
  • You prefer the calibrated pen injector experience.
  • Working with a specialist who prefers branded for clinical reasons.

When compounded is reasonable

  • Cash-pay (no coverage, high deductible, or excluded coverage).
  • Comfortable with the 503A/503B regulatory framework and have verified your provider's pharmacy partners.
  • Accept the trade-off of not having FDA-approved finished-product status.

How to evaluate a compounded provider

  • Are pharmacy partners named (not just "U.S. compounding pharmacy")?
  • Is 503A or 503B classification disclosed?
  • What standards (USP <797>, USP <85>) are referenced?
  • Is third-party batch testing mentioned (especially for 503B lots)?
  • Is clinical oversight (licensed clinician) clearly described?

For an example of strong pharmacy disclosure, see our NexLife review.